Identification of the Calcium Binding Site and a Novel Ytterbium Site in Blood Coagulation Factor XIII by X-ray Crystallography*

Brian A. FoxDagger , Vivien C. Yee§, Lars C. Pedersen, Isolde Le Trongparallel , Paul D. Bishop**, Ronald E. Stenkampparallel , and David C. TellerDagger Dagger Dagger

From the Dagger  Department of Biochemistry, University of Washington, Seattle, Washington 98195, the § Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195,  NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709, the parallel  Department of Biological Structure, University of Washington, Seattle, Washington 98195, and ** ZymoGenetics Inc., Seattle, Washington 98105

    ABSTRACT
Top
Abstract
Introduction
References

The presence or absence of calcium determines the activation, activity, oligomerization, and stability of blood coagulation factor XIII. To explore these observed effects, we have determined the x-ray crystal structure of recombinant factor XIII A2 in the presence of calcium, strontium, and ytterbium. The main calcium binding site within each monomer involves the main chain oxygen atom of Ala-457, and also the side chains from residues Asn-436, Asp-438, Glu-485, and Glu-490. Calcium and strontium bind in the same location, while ytterbium binds several angstroms removed. A novel ytterbium binding site is also found at the dimer two-fold axis, near residues Asp-270 and Glu-272, and this site may be related to the reported inhibition by lanthanide metals (Achyuthan, K. E., Mary, A., and Greenberg, C. S. (1989) Biochem. J. 257, 331-338). The overall structure of ion-bound factor XIII is very similar to the previously determined crystal structures of factor XIII zymogen, likely due to the constraints of this monoclinic crystal form. We have merged the three independent sets of water molecules in the structures to determine which water molecules are conserved and possibly structurally significant.

    INTRODUCTION
Top
Abstract
Introduction
References

The biological importance of factor XIII (fXIII)1 (EC 2.3.2.13) lies in its ability to form new covalent bonds between protein chains. This activity was first recognized while studying blood coagulation; fXIII was required to form an insoluble clot (1). The activated form of fXIII covalently cross-links two fibrin molecules via an isopeptide bond between the side chains of a glutamine and a lysine located in the C-terminal region of the gamma -chain. Over a longer time period in coagulation, it also forms cross-links between the alpha - and gamma -chains of fibrin (2), and between alpha 2-anti-plasmin and fibrin (3). fXIII has been shown to react with more than fibrin (4), and it has recently been found in brain tumors (5) and arthritic joints (6), and there are cases of fXIII deficiencies (7, 8). Factor XIII is a member in the family of transglutaminases (TGases), which have a wide range of biological functions (9).

Like most coagulation factors, fXIII is synthesized as a zymogen and then cleaved by a protease to become an active enzyme. The structure of fXIII zymogen was determined several years ago (10, 11). In this crystal form, the active site cysteine, Cys-314, is inaccessible to solvent and is not available for catalysis.

Physiologically, calcium ions are required for fXIII activation and for TGase activity. In the blood, activation of circulating fXIII requires thrombin cleavage, calcium ions (1.5 mM) (12-14), and fibrin(ogen) (15). High levels of calcium (>50 mM) can activate fXIII without the use of thrombin (15), and it has recently been shown that platelet fXIII can be activated nonproteolytically in vivo (16).

Based on the amino acid sequence, the calcium binding site was predicted to be in a region (residues 468-479) with high similarity to the EF-hand motif (17, 18). The main calcium binding site, as seen in the preliminary crystallographic study (19), involves residues Asn-436, Asp-438, Ala-457, Glu-485, and Glu-490. C-terminal truncation experiments removing several residues from the calcium binding pocket show a total loss of enzymatic activity (20). Site-directed mutagenesis of the glutamate residues in the calcium binding region of guinea pig liver TGase decreases its sensitivity to calcium, while maintaining some enzymatic activity (21).

There is further in vitro evidence that calcium and other divalent cations have effects on proteolytic susceptibility (22) and heat stability (23). Several lanthanide ions have been shown to replace calcium ions during fXIII activation (10-40 µM). Furthermore, these lanthanide ions can inhibit fXIII activity when the ion concentration is greater than 40 µM (24). Most of these effects occur when the calcium ion is in the millimolar range, and with the lanthanide ion in the micromolar range.

We have solved the structures of recombinant fXIII zymogen complexed with calcium, strontium, and ytterbium to determine the structural effects of these cations on fXIII. The goal in using the latter two cations was to positively identify the electron-rich ions in the electron density maps. All three ions bind to the same pocket. We have found an additional ytterbium binding site, hypothesized to be the lanthanide inhibition site.

    EXPERIMENTAL PROCEDURES

Crystallization and Data Collection-- Crystals of recombinant human factor XIII A2 (166 kDa) (25) zymogen were grown from 1, 2-propanediol (24%) and sodium potassium phosphate buffer (100 mM) at pH 6.2. The crystals show the symmetry of space group P21 with two monomers in the asymmetric unit. The ion-bound crystals were obtained by soaking zymogen crystals for 1-2 days in 90 mM CaCl2, 120 mM SrCl2, or 2 mM YbCl3 in an artificial mother liquor of 1,2-propanediol (24%) and MES buffer at pH 6.2. Data for the calcium soaked crystal were collected at the Stanford Synchrotron Radiation Laboratory on beamline 9-1 with a MAR image plate detector at -170 °C. For the strontium and ytterbium crystals, data were collected in-house at room temperature on an R-AXIS IIc image plate detector equipped with a Rigaku RU200 rotating anode generator. The calcium crystal yielded data to 2.1 Å, and the strontium and ytterbium data sets diffracted to 2.5 Å (Table I).

Structure Refinement-- Our previously refined P21 fXIII zymogen structural model was used to generate initial phases for all three ion-bound structures. The initial R (Sigma  ||Fobs- |Fcalc||/Sigma |Fobs|) was 48.2%, 36.8%, and 31.0% for the calcium, strontium, and ytterbium structures, respectively.

The calcium refinement began with a series of rigid body minimization steps at 8-3.5 Å resolution using X-PLOR (26). The first rigid body refinement used two monomers, while the next was composed of the eight domains; finally, a refinement with 193 secondary structure elements (helix, strand, loop) was performed. After those three steps, the R had dropped from 48.2% to 32.9%. This multistep rigid body procedure was used because of the cryogenic data collection and higher initial R factor. This rendered a 2.3% lower R factor than if a simple two-monomer rigid body step was used. From here, the resolution was expanded to 2.2 Å in six steps by alternating rigid body (with 193 groups) and positional least square refinements. The R dropped to 27.9% with an Rfree of 38.6%. Simulated annealing with slow cooling from 2000 to 300 K, followed by a round of positional and B value least squares minimization gave a drop in R of 0.4% and Rfree of 1.6%. Refinement continued through several rounds of map fitting with the program XtalView (27) and least squares and dynamics minimization. The program DDQ (28) was used to assess model and map quality during the refinement procedure. Waters were added at positions with difference electron density peaks greater than 3.0 sigma , which also were within hydrogen bonding distance of the protein or other waters. In the end, the structure was refined with overall anisotropic scaling of the data along with a bulk solvent model and a resolution of 20.0-2.1 Å; this resulted in an R of 22.7% and Rfree of 31.2%, with a total of 1001 waters (Table I).

The strontium and ytterbium refinements were carried out over the resolution range of 10-2.5 Å for all steps. The X-PLOR refinement began with a positional and individual B value minimization of the starting model, which lowered the R to approximately 27%, and was followed by adding two ions per dimer at the highest peaks in the difference map (Table II). It then proceeded through more cycles of least squares minimization and manual map fitting in the program O (29). In the ytterbium refinement, three additional 10-12 sigma  difference peaks were observed near the non-crystallographic two-fold axis within the dimer, and three ions were added (sites 3, 4, and 5). Furthermore, one additional Yb3+ ion was added at a 10 sigma  difference peak (site 7), which is located at a crystallographic contact with another dimer. Following refinement of these four ions in the structure, one more difference peak appeared on the two-fold axis, so another ytterbium ion was added (site 6). After further refinement and map fitting, the R decreased to 19.8% (strontium) and 22.0% (ytterbium), and waters were placed at chemically reasonable 3 sigma  difference peaks. Additionally, a strong difference peak about 2 Å away from the main Yb3+ (site 2) in monomer B was identified, and a new Yb3+ ion (site 8) was added with an occupancy of 0.25, while the occupancy of the original Yb3+ ion was reduced to 0.75. Several more rounds of least squares refinement, map fitting, and water addition led to a final R of 18.3% and 18.8%, an Rfree of 27.5% and 28.1%, and 230 and 265 waters for the strontium and ytterbium complexes, respectively (Table I).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Data collection and refinement statistics
NA, not available; SSRL, Stanford Synchrotron Radiation Laboratory.

The Protein Data Bank codes for the calcium, strontium, and ytterbium structures are 1GGU, 1BL2, and 1GGY, respectively. Figures in this report were generated with Molscript (30), Raster3D (31), and XtalView (27).

    RESULTS

Overall Structure-- Each monomer of fXIII in the dimer has 731 residues and consists of four domains: the beta -sandwich, the catalytic core, and barrels 1 and 2 (Fig. 1). The active site residues Cys-314, His-373, and Asp-396 are not accessible to solvent, as in the zymogen structure. The calcium binding site is located in the core domain, near the surface of the protein. The root mean square deviation (r.m.s.d.) between all atoms from the strontium- and ytterbium-bound structures compared with the starting ion-free fXIII zymogen structure is less than 0.85 Å. The calcium structure, on the other hand, differs from the two cation structures and the starting structure with an r.m.s.d. of 1.1 Å. This higher atomic coordinate deviation is likely due to the cryogenic data collection for the calcium structure.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 1.   Overall structure of the factor XIII dimer. Panel A is the dimer looking down the two-fold axis. The domains, activation peptide (AP), and N and C termini of one monomer are labeled. Panel B shows one monomer, rotated 90° with the domains, N terminus, active site (AS), and ion sites labeled. For both views, three unique spheres are also shown: novel ytterbium site on the dimer two-fold axis (medium gray), active site (light gray), and main ion site (dark gray).

Due to uninterpretable electron density, the monomers are missing various numbers of residues from the N terminus (residues 1-8), the linker between the activation peptide and the beta -sandwich (residues 30-43), the region between the core and barrel 1 (residues 508-516), and the C terminus (residues 728-731). Most of the residues were well resolved, with 90% having average B values of less than 60 Å2.

Structure Quality-- Less than 0.4% of the torsion angles are in the forbidden regions of the Ramachandran diagram, as reported by PROCHECK (32). Three peptide bonds in each monomer are in the cis conformation (10, 33). One involves a proline residue, 410-411, and the other two do not, 310-311 and 425-426. The structures are reasonable as judged by DDQ (28), Verify3D (34), ERRAT (35), and WHATIF (36).

Main Ion Site-- The main ion binding site is near the interface between the catalytic core and barrel 1 (Fig. 1), and the ion binding helix (residues 485-501) is in contact with the other monomer. The calcium and strontium atoms superimpose within this site, while the main ytterbium ion is 2.7 Å from their location (Fig. 2). The mean peak sizes in an early difference map were about 4, 7, and 11 sigma  for the calcium, strontium, and ytterbium ions, respectively (Table II). When water molecules replaced the calcium ions at these positions, their B values refined to about 14-23 Å2. However, for the strontium and ytterbium sites, the B values of the replaced water molecules refine down to 2 Å2, the minimum allowable value. This analysis implies that a water molecule in this location does not have enough electrons to adequately match the strontium and ytterbium x-ray diffraction data.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 2.   The main calcium binding site. The calcium (red), strontium (yellow), ytterbium (blue), and zymogen (gray) structures from monomer B are superimposed in this figure. Both positions of the Yb3+ ion are shown, with the weaker ion represented by the smaller sphere and labeled with parentheses. The water molecules in this region have been omitted for simplicity.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Statistics for the cations

The main cation site consists of a pocket with negatively charged side chains of Asn-436, Asp-438, Glu-485, and Glu-490 plus the main chain oxygen of Ala-457. All three ion-bound structures and the zymogen structure overlap quite closely in this region (Fig. 2). Table III lists the oxygen atoms that are potentially involved in coordinating each cation. The main chain oxygen from Ala-457 is the main protein ligand for the Ca2+ and Sr2+ ions, as indicated by its low B value and its distance from the metals. The Yb3+ ion is farther from Ala-457 and closer to Glu-485 and Glu-490. The B values for the residues in the region from 484 to 490 are higher than average, and the electron density is weak.

                              
View this table:
[in this window]
[in a new window]
 
Table III
The distance and B value of all oxygen atoms within 4.0 Å of the specified ion of each site

The ion site in monomer B of the calcium structure has six putative ligands arranged in a distorted bipyramidal arrangement (Fig. 3). One protein atom (O-Ala-457) and up to five waters are within 4.0 Å of the ion. Residues Asp-438, Asn-436, and Glu-490 are hydrogen-bonded to several of these waters. Fewer waters were identified in the strontium and ytterbium structures due to the lower resolution data.


View larger version (89K):
[in this window]
[in a new window]
 
Fig. 3.   Stereoview of the electron density for the calcium site. Shown is the final 2|Fo- |Fc| electron density (1.2 sigma  contour) for the calcium binding site in monomer B of the calcium structure. The residues are labeled with the single-letter code for amino acid and residue number. Waters from Table III are labeled, and all waters are shown as crosses. Two waters (300L and 23L) have visible electron density at a lower contour level (0.5 sigma ; not shown).

The ytterbium ion has one monodentate (Asn-436) and two bidentate (Glu-485, Glu-490) ligands provided by the protein and nearby water molecules. The ion site in monomer B of the ytterbium structure has two alternate positions for the Yb3+ ion 1.8 Å from each other. The occupancies for each ion were chosen such that they refined to equal B values and summed to 1. It is unlikely that the weaker Yb3+ ion (site 8) is a negative chloride ion because it is very close to the position of the positive calcium ion from the calcium structure, which implies that its location is suitable for only positive ions. The ligand distances between the Yb3+ ion and the oxygen atoms are as low as 1.98 Å, but this is consistent with other Yb3+-oxygen distances, as observed in the Protein Data Bank (codes 1CNT (37), 1NCG and 1NCH (38), 1YTT (39), and 2BOP (40)).

Novel Ytterbium Site-- Four large electron density peaks near the non-crystallographic dimer two-fold axis form a nearly perfect tetrahedron with an edge length of approximately 3.6 ± 0.1 Å (Fig. 4 and Table II). Furthermore, a similar tetrahedron is observed in the ytterbium soak of the orthorhombic crystal form (10) of fXIII (data not shown). After modeling four ytterbium ions at 0.25 occupancy into the electron density, the B values refined to 17, 23, 23, and 10 Å2. Placing waters at full occupancy in these locations gave B values that refined to 2 Å2. No ions or solvent molecules exist in the same location in the Ca2+- or Sr2+-bound crystal structures. Residues Asp-270, Asp-271, and Glu-272 of each monomer are in this region, but the electron density does not specify one distinct conformation for the side chains, and the B values are quite high.


View larger version (82K):
[in this window]
[in a new window]
 
Fig. 4.   Stereoview of the electron density for the novel ytterbium binding site. Shown is the final 2|Fo- |Fc| electron density (1.0 sigma  and 5.0 sigma  contour levels) for the novel ytterbium site. This tetramer of ions is located on the dimer two-fold non-crystallographic axis. The residues are labeled with the single-letter code for amino acid and residue number. The top residues are from monomer A, and the bottom residues are from monomer B.

Water Analysis-- After the refinement of the three structures, waters were grouped into subsets based on their occurrence in each crystal. If waters from different structures were located within 2.4 Å from each other, they were considered equivalent, and given the same chain identification and residue number in the Protein Data Bank files. In some cases, the determination of equivalent waters was made on the basis of their B values and local protein differences between structures. A Venn diagram was constructed (Fig. 5) showing the seven different subsets from the three independent groups. If a water from one structure had no equivalent waters from another structure, it was given a particular chain identifier (L for calcium, R for strontium, Y for ytterbium). If a water molecule was in only two different structures, it was given the same residue number and chain identification (U for calcium and strontium, V for calcium and ytterbium, W for strontium and ytterbium). Finally, water molecules that exist in all three structures were given the chain identification of S along with the same residue number.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Venn diagram of the resulting subsets of water molecules from the three ion structures. Shown above are the total number of waters and their assigned chain identification for each subset. Each water is placed in only one of the possible seven subsets.

The average and standard deviation of B values and Cbeta density for the water molecules are presented in Table IV. The Cbeta density (41) estimates the amount of burial at each water site by counting the number of Cbeta atoms within 10 Å of the water site. It has a numerical range of 2-30 atoms, which qualitatively ranges from highly exposed to deeply buried.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Water subsets: average B values and Cbeta densities
Average Cbeta density is the average of the number of Cbeta atoms within 10 Å of each water in the subset. PDB, Protein Data Bank; ID, identification.

Many of the water molecules are located in sites common to all three structures. Water molecules that are present in all three structures (subset S) have B values about 10 Å2 lower than unique waters. Likewise, these common waters are more buried, as shown by the 50% larger number of nearby Cbeta atoms.

    DISCUSSION

Overall Structure-- Calcium and other cations have definite effects on fXIII behavior in solution. The ion soaking concentrations in the calcium and strontium crystals were above the level at which conformational changes, such as enzyme activation, are expected. No significant conformational differences between the ion complex and the zymogen structure are seen. Two complementary reasons for this lack of conformational change are: 1) the active conformation of the enzyme cannot pack in this crystal form, and 2) some other molecule, such as a substrate or inhibitor, is required to stabilize fXIII in its active form.

Packing interactions in the monoclinic crystal form restrict any major conformational changes induced in fXIII. Crystallization of thrombin cleaved fXIII in the presence of 1.5 mM calcium has resulted in the same crystal form and the same conformation (42). Furthermore, co-crystallization of 45 mM CaCl2 with fXIII has yielded this monoclinic crystal form with the same conformation (43). Structurally, one residue that must move to expose the active site Cys-314 is Tyr-560, located in barrel 1. In this space group, barrel 1 is trapped in place by crystal contacts. We therefore believe that this crystal form is incompatible with the active form of fXIII.

The biochemical experiments used to demonstrate the effects of calcium and other cations on fXIII use either a substrate or inhibitor to measure whether the enzyme is active. We propose that one of these molecules is another requirement for the stabilization of the active form. In the presence of calcium, the inactive form of fXIII is in equilibrium with the active conformation. During crystallization, the inactive form is more likely to be crystallized; thus, mass action causes any active fXIII to change to its inactive conformation. The presence of a substrate or inhibitor might stabilize the active conformation further and allow crystallization in a new crystal form. This proposal is in line with the known effect of fibrin(ogen) in facilitating the activation of fXIII (14, 44).

Main Ion Site-- Some ideas about calcium activation can be gained from the location of the main binding site with respect to other features on the molecule. First, the calcium binding pocket is only 10 Å from barrel 1, which is responsible for partially blocking the active site via Tyr-560. The bound ion may induce some dynamical changes in nearby barrel 1, including exposure of the active site. Additionally, one end of the calcium binding helix forms close contacts with the other monomer. This may allow for allosteric communication between the calcium binding site of one monomer and the active site of the other, as described by Hornyak and Shafer (14).

The residues involved in calcium binding are well conserved within the TGase family. The coordination geometry for the calcium and strontium is not ideal; many of the putative ligands are water molecules, and the metal-ligand distances are somewhat longer than observed for calcium complexes in other proteins (45) (Table III). The B values for these residues are not much different from those observed for the ion free structures. These observations are consistent with fXIII's millimolar binding affinity (15) for Ca2+ ions. The Yb3+ ion, which binds more tightly, is in a slightly different location and has more coordinating protein atoms with fewer water ligands. This ion has a smaller radius and has a higher charge than divalent cations, so the fact that it has a different binding location is not unreasonable.

Novel Ytterbium Site-- The four ytterbium ions on the dimer two-fold axis are modeled with 1/4 occupancy each. The interatomic distances are too small to allow multiple positively charged ions to be present concurrently. They are time and space averaged throughout the crystal so that only one ion is in the site at any given time. This multiplicity of the ion has made it difficult to model the protein ligands.

We postulate that this tetrahedron of partial occupancy ions is the lanthanide inhibition site. Achyuthan et al. (24) have observed that the addition of lanthanide ions above 40 µM to thrombin-cleaved fXIII results in the non-competitive inhibition of fXIII. This inhibition cannot be reversed by a 200-fold molar excess of calcium ions. Furthermore, when the level of the lanthanide ion is between 10 and 40 µ M, fXIII can be activated by thrombin cleavage as in the presence of calcium. These results (24) could be explained by multiple lanthanide binding sites. The main ion site, observed in all three ion-bound structures, is required for proper thrombin activation, and the novel Yb3+ site, which has a slightly weaker affinity, is responsible for the inhibition of fXIII. Given the soaking concentration of 2 mM in this data set, both ions sites are filled. Functionally, the location at the dimer interface could potentially destabilize the quaternary structure. Additionally, the residues that form the lanthanide inhibition site (Asp-270 to Glu-272) are only 5 residues away from Trp-279, which may play an important role in catalysis (11).

Waters-- Grouping the waters into subsets based on their presence in multiple structures has been helpful in identifying structurally significant waters. One example is that of water 6059S (Fig. 6). This water in the core domain binds to several residues that are fully conserved in the TGase family (Thr-466, Lys-467, Arg-333, and Tyr-204). The water is located at the separation fork of a pair of beta  strands. One half of each strand forms a paired sheet, and the other half of each strand diverges nearly at a right angle. Furthermore, these strands are linked with functionally important parts of the protein. One strand pairs with the strand containing the active site His-373; and the other strand contains a ligand (Ala-457) for the calcium binding site. Monomer B also contains a water molecule in this location (6009S). We believe this water is structurally important for maintaining the unique conformation of this pair of strands.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 6.   Structurally significant water molecule. Water 6059S is shown as a sphere with several secondary structure elements nearby. The residues near this water are also shown. The active site residue His-373 and calcium binding ligand Ala-457 are shown.

Many other waters in this subset S are contacting conserved residues in this protein, and it is possible that some of these waters may help to explain natural fXIII deficiency mutations or other interesting structural and evolutionary features. In fact, of the 18 identified missense mutations (46-49)2 that cause a fXIII deficiency, half are contacting at least one conserved water from subset S. The probability of this happening by chance is 5%.

Conclusion-- There are no major conformational changes between the different ion-bound fXIII structures and the zymogen. This is likely due to crystal packing interactions and the lack of a substrate or inhibitor molecule to stabilize the active conformation. The location of the main ion binding site provides ideas about the mechanism of calcium activation, such as its proximity to barrel 1 and its contact with the other monomer. The novel ytterbium binding site, on the dimer two-fold axis, could be responsible for the biochemically observed lanthanide inhibition. The procedure of finding common waters between the structures is a new method for identifying particular waters and residues that may be structurally significant and important for the function of fXIII. Overall, these three structures positively identify the calcium binding site in factor XIII.

    ACKNOWLEDGEMENT

We thank the Murdock Foundation for their support of facilities in the Biomolecular Structure Center.

    FOOTNOTES

* This work was supported by National Institutes of Health Training Grant GM08268 (to B. A. F.) and by National Institutes of Health Grant HL50355.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The atomic coordinates and structure factors (accession codes 1GGU, 1BL2, and 1GGY for the calcium-, strontium-, and ytterbium-bound factor XIII coordinates, respectively) have been deposited in the Protein Data Bank, Brookhaven National Laboratory, Upton, NY.

Dagger Dagger To whom correspondence should be addressed: Dept. of Biochemistry, University of Washington, Box 357350, Seattle, WA 98195. Tel.: 206-543-1756; Fax: 206-685-1792; E-mail: teller{at}u.washington.edu.

    ABBREVIATIONS

The abbreviations used are: fXIII, factor XIII; TGase, transglutaminase; r.m.s.d., root mean square deviation; MES, 4-morpholineethanesulfonic acid.

2 H. Mikkola, personal communication.

    REFERENCES
Top
Abstract
Introduction
References

  1. Laki, K., and Lorand, L. (1948) Science 108, 280
  2. Lewis, K. B., Teller, D. C., Fry, J., Lasser, G. W., and Bishop, P. D. (1997) Biochemistry 36, 995-1002[CrossRef][Medline] [Order article via Infotrieve]
  3. Ichinose, A., Tamaki, T., and Aoki, N. (1983) FEBS Lett 153, 369-371[CrossRef][Medline] [Order article via Infotrieve]
  4. Muszbek, L., Ádány, R., and Mikkola, H. (1996) Crit. Rev. Clin. Lab. Sci. 33, 357-421[Medline] [Order article via Infotrieve]
  5. Bárdos, H., Molnár, P., Cdécsei, G., and Ádány, R. (1996) Blood Coagul. Fibrinolysis 7, 536-548[Medline] [Order article via Infotrieve]
  6. Carmassi, F., De Negri, F., Morale, M., Song, K. Y., and Chung, S. O. (1996) Semin. Thromb. Hemostasis 22, 489-496[Medline] [Order article via Infotrieve]
  7. Kitchens, C. S., and Newcomb, T. F. (1979) Medicine 58, 413-428[Medline] [Order article via Infotrieve]
  8. Board, P. G., Losowsky, M. S., and Miloszewski, K. J. (1993) Blood Rev. 7, 229-242[Medline] [Order article via Infotrieve]
  9. Greenberg, C. S., Birckbichler, P. J., and Rice, R. H. (1991) FASEB J. 5, 3071-3077[Abstract/Free Full Text]
  10. Yee, V. C., Pedersen, L. C., Le Trong, I., Bishop, P. D., Stenkamp, R. E., and Teller, D. C. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7296-7300[Abstract]
  11. Pederson, L. C., Yee, V. C., Bishop, P. D., Le Trong, I., Teller, D. C., and Stenkamp, R. E. (1994) Protein Sci. 3, 1131-1135[Abstract/Free Full Text]
  12. Curtis, C. G., Brown, K. L., Credo, R. B., Domanik, R. A., Gray, A., Stenberg, P., and Lorand, L. (1974) Biochemistry 13, 3774-3780[Medline] [Order article via Infotrieve]
  13. Cooke, R. D., and Holbrook, J. J. (1974) Biochem. J. 141, 79-84[Medline] [Order article via Infotrieve]
  14. Hornyak, T. J., and Shafer, J. A. (1991) Biochemistry 30, 6175-6182[Medline] [Order article via Infotrieve]
  15. Credo, R. B., Curtis, C. G., and Lorand, L. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 4234-4237[Abstract]
  16. Muszbek, L., Haramura, G., and Polgár, J. (1995) Thromb. Haemostasis 73, 702-705[Medline] [Order article via Infotrieve]
  17. Takahashi, N., Takahashi, Y., and Putnam, F. W. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8019-8023[Abstract]
  18. Ichinose, A., and Davie, E. W. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 5829-5833[Abstract]
  19. Yee, V. C., Le Trong, I., Bishop, P. D., Pedersen, L. C., Stenkamp, R. E., and Teller, D. C. (1996) Semin. Thromb. Hemostasis 22, 377-384[Medline] [Order article via Infotrieve]
  20. Lai, T. S., Achyuthan, K. E., Santiago, M. A., and Greenberg, C. S. (1994) J. Biol. Chem. 269, 24596-24601[Abstract/Free Full Text]
  21. Ikura, K., Yu, C., Nagao, M., Sasaki, R., Furuyoshi, S., and Kawabata, N. (1995) Arch. Biochem. Biophys. 318, 307-313[CrossRef][Medline] [Order article via Infotrieve]
  22. Mary, A., Achyuthan, K. E., and Greenberg, C. S. (1988) Arch. Biochem. Biophys. 261, 112-121[Medline] [Order article via Infotrieve]
  23. De Backer-Royer, C., and Meunier, J. C. (1992) Int. J. Biochem. 24, 637-642[Medline] [Order article via Infotrieve]
  24. Achyuthan, K. E., Mary, A., and Greenberg, C. S. (1989) Biochem. J. 257, 331-338[Medline] [Order article via Infotrieve]
  25. Bishop, P. D., Teller, D. C., Smith, R. A., Lasser, G. W., Gilbert, T., and Seale, R. L. (1990) Biochemistry 29, 1861-1869[Medline] [Order article via Infotrieve]
  26. Brunger, A. T. (1992) X-PLOR Version 3 (1): A System for X-ray Crystallography and NMR, Yale University Press, New Haven, CT
  27. McRee, D. E. (1992) J. Mol. Graphics 10, 44-46[CrossRef]
  28. van den Akker, F., and Hol, W. G. J. (1999) Acta Crystallogr. Sect. D 55, 206-218[Medline] [Order article via Infotrieve]
  29. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Acta Crystallogr. Sect. A 47, 110-119[CrossRef][Medline] [Order article via Infotrieve]
  30. Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 946-950[CrossRef]
  31. Merritt, E. A., and Bacon, D. J. (1997) Methods Enzymol. 277, 505-524
  32. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) J. Appl. Crystallogr. 26, 283-291[CrossRef]
  33. Weiss, M. S., Metzner, H. J., and Hilgenfeld, R. (1998) FEBS Lett. 423, 291-296[CrossRef][Medline] [Order article via Infotrieve]
  34. Eisenberg, D., Luthy, R., and Bowie, J. U. (1997) Methods Enzymol. 277, 396-404[Medline] [Order article via Infotrieve]
  35. Colovos, C., and Yeates, T. O. (1993) Protein Sci. 2, 1511-1519[Abstract/Free Full Text]
  36. Hooft, R. W. W., Vriend, G., Sander, C., and Abola, E. E. (1996) Nature 381, 272[Medline] [Order article via Infotrieve]
  37. McDonald, N. Q., Panayotatos, N., and Hendrickson, W. A. (1995) EMBO J. 14, 2689-2699[Abstract]
  38. Shapiro, L., Fannon, A. M., Kwong, P. D., Thompson, A., Lehmann, M. S., Grubel, G., Legrand, J. F., Als-Nielsen, J., Colman, D. R., and Hendrickson, W. A. (1995) Nature 374, 327-337[CrossRef][Medline] [Order article via Infotrieve]
  39. Burling, F. T., Weis, W. I., Flaherty, K. M., and Brunger, A. T. (1996) Science 271, 72-77[Abstract]
  40. Hegde, R. S., Grossman, S. R., Laimins, L. A., and Sigler, P. B. (1992) Nature 359, 505-512[CrossRef][Medline] [Order article via Infotrieve]
  41. Sippl, M. J. (1993) J. Comput. Aided Mol. Des. 7, 473-501[Medline] [Order article via Infotrieve]
  42. Yee, V. C., Pedersen, L. C., Bishop, P. D., Stenkamp, R. E., and Teller, D. C. (1996) Thromb. Res. 78, 389-97[CrossRef]
  43. Pedersen, L. C. (1994) X-ray Structure Determination of Factor XIII.Ph.D. dissertation, University of Washington, Seattle, WA
  44. Greenberg, C. S., Achyuthan, K. E., and Fenton, J. W., II (1987) Blood 69, 867-871[Abstract]
  45. McPhalen, C. A., Strynadka, N. C. J., and James, M. N. G. (1991) Adv. Protein Chem. 42, 77-144[Medline] [Order article via Infotrieve]
  46. Mikkola, H., and Palotie, A. (1996) Semin. Thromb. Hemostasis 22, 393-398[Medline] [Order article via Infotrieve]
  47. Anwar, R., Stewart, A. D., Miloszewski, K. J. A., Losowsky, M. S., and Markham, A. F. (1995) Br. J. Haematol. 91, 728-735[Medline] [Order article via Infotrieve]
  48. Aslam, S., Yee, V. C., Narayanan, S., Duraisamy, G., and Standen, G. R. (1997) Br. J. Haematol. 98, 346-352[Medline] [Order article via Infotrieve]
  49. Takahashi, N., Tsukamoto, H., Umeyama, H., Castaman, G., Rodeghiero, F., and Ichinose, A. (1998) Blood 91, 2830-2838[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.